Soluble Transferrin Receptor and

This study aimed To elucidate the relation between s TFR with the most commonly used markers of iron state and their significance in the diagnosis of iron deficiency in hemodialysis patients.To achieve such target we selected 20 Patients with end stage renal disease on regular hemodialysis receiving rH-Epo with a dose range from 40:60 U/kg/ dose Two times weekly by the subcutaneous route, 20 patient with end stage renal disease on regular hemodialysis not receiving rH-Epo and 20 healthy subjects as control group.All subjects were selected to be above the Age of 20 years, free from hepatic and endocrinal disorders other than diabetes and not Receiving blood Transfusion or iron therapy and subjected to complete clinical examination, and the following laboratory investigations (CBC, serum protein, albumin, alanine transferase, aspartate transferase, serum creatinine, Blood urea, serum iron, serum ferritin, TIBC, Transferrin saturation (TS) C-reactive protein and serum soluble transferrin receptors (sTFR)).The study showed significant increase in sTFR in patients with chronic renal failure in both group III and II compared to controls but it was significantly higher in group III compared II (P<0.01).Improvement of iron mobilization and metabolism in group II due to treatment with erythropietin was evidenced by the significant difference in sTFR on comparing group III to II with decreased levels in group II and also, evidenced by significant higher levels of haemolgobin in group II compared to group III.